Tag Archives: Elemer Piros

Cantor Fitzgerald Reiterates a Buy Rating on Ocular Therapeutix

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Ocular Therapeutix (NASDAQ: OCUL), with a price target of $22. The company’s shares closed yesterday at $6.27. Piros observed: “We rate Ocular Therapeutix (OCUL) 12-month

Global Blood Therapeutics Receives a Buy from Cantor Fitzgerald

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Global Blood Therapeutics (NASDAQ: GBT), with a price target of $96. The company’s shares closed yesterday at $38.70. Piros wrote: “: We are reiterating our

Cantor Fitzgerald Reaffirms Their Buy Rating on Apellis Pharmaceuticals Inc

In a report released yesterday, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Apellis Pharmaceuticals Inc (NASDAQ: APLS), with a price target of $52. The company’s shares closed yesterday at $23.50. Piros commented: “We reiterate our OW rating

Cantor Fitzgerald Reaffirms Their Buy Rating on Aldeyra Therapeutics

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX) today and set a price target of $23. The company’s shares opened today at $8.35. Piros wrote: “: We are reiterating our Overweight rating and 12-month

Cantor Fitzgerald Sticks to Their Buy Rating for Mesoblast Ltd

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Mesoblast Ltd (NASDAQ: MESO) yesterday and set a price target of $23. The company’s shares closed yesterday at $5.54. Piros commented: “We rate Mesoblast Overweight. We believe the company’s platform

Cantor Fitzgerald Believes Arrowhead Research (NASDAQ: ARWR) Won’t Stop Here

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Arrowhead Research (NASDAQ: ARWR), with a price target of $13. The company’s shares opened today at $11.68, close to its 52-week high of $11.84. Piros